Henric Bjarke
Geen lopende functies
Vermogen: 456 560 $ op 30-04-2024
Profiel
Henric Bjarke held several positions in different companies.
He was a Senior Director at Oldtech, Inc. and Vice President-Marketing at Actavis, Inc. He was also the VP-Global Metabolic Disorders Franchise at Alexion Pharmaceuticals, Inc. from 2012 to 2015.
Before that, he worked as a Specialty Sales Representative at Pharmacia AB.
From 2015 to 2017, he was the Chief Commercial Officer & Senior Vice President at IVERIC bio, Inc. He was also a Principal at Direct Enterprise, Inc. before becoming the Chief Operating Officer & Senior Vice President at Inozyme Pharma, Inc. in 2017.
Mr. Bjarke obtained his undergraduate degree from the University of Uppsala.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
INOZYME PHARMA, INC.
0.17% | 17-04-2023 | 105 441 ( 0.17% ) | 456 560 $ | 30-04-2024 |
Eerdere bekende functies van Henric Bjarke
Bedrijven | Functie | Einde |
---|---|---|
INOZYME PHARMA, INC. | Chief Operating Officer | 31-12-2022 |
IVERIC BIO, INC. | Corporate Officer/Principal | 17-03-2017 |
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-08-2015 |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Sales & Marketing | - |
Pharmacia AB | Corporate Officer/Principal | - |
Opleiding van Henric Bjarke
University of Uppsala | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
INOZYME PHARMA, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Pharmacia AB | Health Technology |
IVERIC bio, Inc.
IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Direct Enterprise, Inc.
Direct Enterprise, Inc. Medical SpecialtiesHealth Technology Direct Enterprise, Inc. provides on-site drug testing devices. It offers a line of clinical diagnostic products including pregnancy tests, ovulation, Strep-A, Nicotine, and h-pylori. The firm also offers services encompassing medical review, background screening, random drug testing, drug test confirmation, and laboratory services. It also operates an online library of cross-reactivity charts in order to look up a drug by its trade name or by a generic name. The company was founded by Larry Hartselle in 1998 and is headquartered in Huntsville, AL. | Health Technology |